InoLife Technologies Inc. sales and marketing update

InoLife launched its Cytochrome P450 2C1 test in the U.S. to determine a patient's ability to metabolize cardiovascular drug Plavix clopidogrel. Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) ...